Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (201-210 of 238) with videos related to

Pageof 24
Sort By:
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Pageof 24

Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Pageof 24